Bright minds biosciences announces receipt of nasdaq deficiency letter regarding independent director and audit committee requirements

Vancouver, british columbia, feb. 08, 2023 (globe newswire) -- bright minds biosciences inc. (cse:drug) (nasdaq:drug) (“bright minds” or the “company”) announces that it has received a letter (the “deficiency letter”) from the nasdaq stock market llc (“nasdaq”) dated february 2, 2023, stating that following the resignation of dr. williamson from the company's board of directors and audit committee, the company no longer complies with nasdaq's independent director and audit committee requirements as set forth in listing rule 5605.
DRUG Ratings Summary
DRUG Quant Ranking